2019-Present Publications
첨부파일 | - |
---|
[2022]
•
HS Kim, S Ryu, SH Yoon, S Lee, J Song, Y Choi, M Baek, HB Lee, S Jon, “Spheroid culture of ER+ breast cancer patient-derived tumor cells
enriches cancer stem-likecells with EpCAM-/CD49f+ and high ALDH activity and
poor prognostic gene signatures”, Cancer Research (IF: 13.312) (2022
Jun 15)
•
TW Kim, Y Kim, H Keum, W Jung, M Kang,
S Jon, “Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an
effective treatment regimen for a vemurafenib-resistant melanoma”, Molecular
Therapy-Oncolytics (IF: 6.311) (2022 Jun 6)
•
H Park, H Jeon, HJ Cha, J Bang, Y Song, M
Choi, D Sung, WI Choi, JH Lee, JS Woo, S
Jon, S Kim, “Purification of Therapeutic Antibodies Using the Ca2+-Dependent
Phase-Transition Properties of Calsequestrin”, Analytical chemistry (IF:
8.008) (2022 April 7)
•
B Yu, D Yoo, KH Kim, TW
Kim, S Park, Y Kim, Y Son, J Kim, I Noh, CH Whang, J Chung, S Jon, “Effective Combination Immunotherapy through Vessel Normalization Using a
Cancer‐Targeting Antiangiogenic
Peptide–Antibody Hybrid”, Advanced Therapeutics (IF: 5.003) (2022 April)
•
H Keum, D Kim, CH Whang, A Kang, S Lee, W Na, S Jon, “Impeding the Medical Protective Clothing Contamination by a Spray Coating
of Trifunctional Polymers”, ACS omega (IF: 4.132) (2022 March 15)
•
S RYU, HS Kim, SH Yoon, S Lee, J Song, M
Baek, HB Lee, S Jon, W Han, “Analysis of immunophenotyping of patient-derived primary breast cancer
cells according to the medium composition and culture method”, CANCER
RESEARCH (IF: 13.312) (2022 February 15)
•
SH Yoon, HS Kim, J Song, S Kwon, S Ryu, M Baek,
S Lee, HB Lee, HG Moon, DY Noh, S Jon,
W Han, “Abstract P5-12-11: NSDHL knockdown decreases tightly cohesive tumorsphere
formation and breast cancer stem cell population”, Cancer Research (IF:
13.312) (2022 February 15)
•
S RYU, HS Kim, SH Yoon, S Lee, J Song, M
Baek, HB Lee, S Jon, W Han, “Abstract P1-05-09: Analysis of immunophenotyping of patient-derived primary
breast cancer cells according to the medium composition and culture method”,
Cancer Research (IF: 13.312) (2022 February 15)
•
H Keum, D Yoo, S Jon, “Photomedicine based on heme-derived compounds”, Advanced Drug
Delivery Reviews (IF: 17.873) (2022 February 3)
•
S Pareek, A Flegle, D Boagni, J Kim, D Yoo, A Trujillo-Ocampo, S Lee, Mao Zhang, S Jon, J Im, “Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft
Versus Host Disease via a Reduction of Systemic and Local Inflammation”,
Frontiers in Immunology (IF: 8.786) (2022 January 1)
[2021]
•
W Ai, S Bae, Q Ke, S Su, R Li, Y Chen, D Yoo, E Lee, S Jon, PM
Kang, “Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury
in Mice”, JAHA (IF: 5.501) (2021 October 19)
•
PE Saw, X Xu, S Kim, S Jon, “Biomedical
Applications of a Novel Class of High-Affinity Peptides”, ACR
(IF: 22.384) (2021 August 18)
•
I Noh, Y Son, W Jung, M Kim, D
Kim, H Shin, YC Kim, S Jon*, “Targeting the
tumor microenvironment with amphiphilic near-infrared cyanine nanoparticles for
potentiated photothermal immunotherapy”, Biomaterials (IF: 12.479)
(2021 August 1)
•
H Keum, D Kim, J Kim, TW Kim, CH Whang, W
Jung, S Jon, “A
bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary
fibrosis”, Biomaterials (IF: 12.479) (2021 June 22)
•
S Kang, Y Kim, Y Shin, JJ Song,
S Jon*, “Antigen-Presenting,
Self-Assembled Protein Nanobarrels as an Adjuvant-Free Vaccine Platform against
Influenza Virus”, ACS Nano (IF: 15.881) (2021 June 11)
•
D Yoo, W Jung, Y Son, S Jon*, “Glutathione-Responsive
Gold Nanoparticles as Computed Tomography Contrast Agents for Hepatic Diseases”,
ACS Applied Bio Materials (2021 May 5)
•
AM Ichzan, SH Hwang, H Cho, C San Fang, S Park, G Kim, J Kim, P Nandhakumar,
B Yu, S Jon, KS Kim, H Yang, “Solid-phase
recombinase polymerase amplification using an extremely low concentration of a
solution primer for sensitive electrochemical detection of hepatitis B viral
DNA”, Biosensors and Bioelectronics (IF: 10.618) (2021 May 1)
•
H Keum, J Kim, D Yoo, TW Kim, C Seo, D
Kim, S Jon*, “Biomimetic
lipid Nanocomplexes incorporating STAT3-inhibiting peptides effectively infiltrate
the lung barrier and ameliorate pulmonary fibrosis”, JCR (IF:
9.776) (2021 April 10)
•
TW Kim, Y Kim, W Jung, DE Kim, H
Keum, Y Son, S Jon*, “Bilirubin
nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis
by modulating dendritic cells”, JCR (IF: 9.776) (2021 March 10)
•
P Er Saw, S Jon, “Understanding
of the entry mechanism of nanoparticles into tumors determines the future
direction of nanomedicine development”, BIO Integration (2021
January 1)
•
PE Saw, X Xu, BR Kang, CH Choi, S Jon, K
Chong*, "Extra-domain B of fibronectin as an alternative target for drug
delivery and a cancer diagnostic and prognostic biomarker for malignant
glioma", Theranostics (IF: 11.556) (2021 January 1)
•
A Bhatia, HS Na, P Nandhakumar, B Yu, S
Jon, J Chung*, H Yang*, “Electrochemical
detection of interleukin-8 in human saliva using a polyenzyme label based on
diaphorase and neutravidin”, Sensors and
Actuators B: Chemical (2021 January 1)
[2020]
•
H Keum, TW Kim, Y Kim, C Seo, Y Son, J Kim, D Kim, W
Jung, CH Whang, S Jon*. "Bilirubin nanomedicine alleviates psoriatic skin
inflammation by reducing oxidative stress and suppressing pathogenic
signaling", JCR 2020, 325 (10), 359-369 (IF: 9.776) (2020
September)
•
J Kim, J Lee, J Lee, H Keum, Y Kim, Y Kim, B Yu, SY
Lee, J Tanaka, Jon S*, MC Choi* "Tubulin-Based
Nanotubes as Delivery Platform for Microtubule-Targeting Agents", Adv.
Mater., 2020, 32, 202002902 (IF: 30.849) (2020 August 18).
•
Kim Y, Kang S, Shin H, Kim TW, Yu B, Kim J, Yoo D, Jon
S*, "Sequential
and timely combination of cancer nanovaccine with immune checkpoint blockade
effectively inhibits tumor growth and relapse", Angew. Chem. Int.
Ed., 2020, ange.202006117 (IF: 15.336) (2020 May 25).
•
Chung CH, Jung W, Keum H, Kim TW, Jon S*, "Nanoparticles Derived From the
Natural Antioxidant, Rosmarinic Acid, Ameliorate Acute Inflammatory Bowel
Disease", ACS Nano, 2020, 0c01018 (IF: 15.881) (2020 May 25).
•
Noh, I, Kim MS, Kim J, Lee DY, Oh D, Kim C, Jon S,
Kim YC*, "Structure-inherent near-infrared bilayer nanovesicles for use as
photoacoustic image-guided chemo-thermotherapy", J. Control.
Release, 2020, 320, 283-292. (IF: 9.776)
•
Kim J, Keum H, Kim H, Yu B, Jung W, Whang CH, Seo
C, Park JH, Jon S*, "Gold nanorods with an ultrathin
anti-biofouling siloxane layer for combinatorial anticancer
therapy", J. Drug Target,
2020, 10.1080/1061186X.2020.1737086. (IF: 5.121)
•
AMJ Haque, P Nandhakumar, G Kim, S Park, B Yu,
NS Lee YH Yoon, S Jon, H Yang*, "Diaphorase-Catalyzed
Formation of a Formazan Precipitate and Its Electrodissolution for Sensitive
Affinity Biosensors", Anal. Chem., 2020, 92, 5,
3932-3939. (IF: 6.986)
•
DY Lee, S Kang, Y Lee, JY Kim, D Yoo, W Jung, S
Lee, YY Jeong, K Lee,
S Jon*, "PEGylated Bilirubin-coated Iron Oxide Nanoparticles as a
Biosensor for Magnetic Relaxation Switching-based ROS Detection in Whole
Blood", Theranostics, 2020, 10 (5), 1997. (IF: 11.556)
[2019]
- J Yoo, NS Rejinold, DY Lee, I Noh, WG Koh, S Jon, YC Kim*, "CD44-mediated methotrexate delivery by hyaluronan coated nanoparticles composed of a branched cell-penetrating peptide", ACS Biomater. Sci. Eng., 2020, 6, 1, 494-504. (IF: 2.78)
- C Jeong, I Noh, NS Rejinold, J Kim, S Jon, YC Kim*, "Self-assembled supramolecular bilayer nanoparticles composed of near-infrared dye as a theranostic nanoplatform to encapsulate hydrophilic drugs effectively", ACS Biomater. Sci. Eng., 2020, 6, 1, 474-484. (IF: 2.78)
- Y Lee, K Sugihara, MG Gillilland, S Jon, N Kamada, JJ Moon*, "Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis", Nat. Mater.,19, 118-126. (IF: 38.887)
- Saw PE*, Lee S, Jon S*, “Naturally Occurring Bioactive Compound-Derived Nanoparticles for Biomedical Applications”, Adv. Therap. 2019; 2, 1800146 (IF: ) (Epub Feb 25) (IF:)
- Kim DY, Hwang K, Ahn J, Seo YH, Kim JB, Lee S, Yoon JH, Kong E, Jeong Y, Jon S, Kim P and Jeong KH*, “Lissajous Scanning Two-photon Endomicroscope for In vivo Tissue Imaging”, Sci. Rep. 2019; 9(1), 3560 (IF: 4.122) (2019 Mar 5).
- Yu B, Hwang D, Jeon H, Kim H, Lee Y, Keum H, Kim J, Lee DY, Kim Y, Chung J and Jon S*, “A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy”, Angew. Chem. Int. Ed. 2019; 58(7), 2005-2010. (IF: 12.102) (Epub 2019 Jan 2; Feb 11).
- Kim H, Hwang DB, Choi M, Lee S, Kang S, Lee Y, Kim S, Chung J* and Jon S*, “Antibody-assisted delivery of a peptide-drug conjugate for targeted cancer therapy”, Mol Pharm. 2019; 16(1), 165-172. (IF: 4.556) (Epub 2018 Dec 6).